



## SELECTED ARTICLES & PUBLICATIONS

- Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, **Song Y**, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. *Current Medical Research and Opinion*. 2020:36(9).
- Bensimon AG, Zhou Z-Y, Jenkins M, **Song Y**, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma in the United States. *Clinical Drug Investigation*. 2020:40(7).
- Pope J, Sawant R, Tundia N, Du EX, Qi CZ, **Song Y**, Tang P, Betts KA. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. *Advances in Therapy*. 2020:37.
- Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, **Song Y**, Pope J. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. *Arthritis Research & Therapy*. 2019:21(1).
- Schultz NM, Penson DF, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. Adverse events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. *Drug Safety*. 2019:43(1).
- **Song Y**, Betts KA, Lu Y, Singh R, Clewell J, Griffith J. Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis. *Rheumatology and Therapy*. 2019:6(2).
- Bensimon AG, Zhou Z-Y, Jenkins M, **Song Y**, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. *Journal of Medical Economics*. 2019:22(10).
- Schultz N, Penson D, Wilson S, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. *Journal of Managed Care & Specialty Pharmacy*. 2019:25(8).
- Yamazaki K, Macaulay D, **Song Y**, Gonzalez YS. Clinical and economic burden of patients with chronic hepatitis C with versus without antiviral treatment in Japan: an observational cohort study using hospital claims data. *Infectious Diseases and Therapy*. 2019:8(2).
- Griffin JD, Yang H, **Song Y**, Kinrich D, Shah M, Bui CN. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild type acute myeloid leukemia: a medical chart study. *European Journal of Haematology*. 2018:102(4).
- Wing VK, **Song Y**, Xiang C, Liu X, Macaulay D, Ponsillo M, Blumentals WA. Incidence of catheter-related complications in Japanese patients with central venous catheters and among patients with short bowel syndrome. *Clinical and Experimental Gastroenterology*. 2018:11.

- Schultz NM, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Kassabian V. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naïve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: A retrospective claims analysis. *Advances in therapy*. 2018:35(10).
- Strand V, Husni ME, Betts KA, **Song Y**, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A. Network meta-analysis and cost per responder of targeted immunomodulators in the treatment of active psoriatic arthritis. *BMC Rheumatology*. 2018:2(1).
- Fishman J, Kalilani L, **Song Y**, Swallow E, Wild I. Antiepileptic drug titration and related health care resource use and costs. *Journal of Managed Care & Specialty Pharmacy*. 2018:24(9).
- Strand V, Tundia N, **Song Y**, Macaulay D, Fuldeore M. Economic burden of patients with inadequate response to targeted immunomodulators in rheumatoid arthritis. *Journal of Managed Care & Specialty Pharmacy*. 2018:24(4).
- **Song Y**, Cho M, Brennan K, Chen BH, Song Y, Manson JE, Hevener AL, You NC, Butch AW, Liu S. Relations of sex hormone levels to leukocyte telomere length in black, Hispanic, and Asian/Pacific Islander postmenopausal women. *Journal of Diabetes*. 2018:10(6).
- Husni ME, Betts KA, Griffith J, **Song Y**, Ganguli A. Benefit-risk trade-offs for treatment decision in moderate-to-severe rheumatoid arthritis: Focus on the patient perspective. *Rheumatology International*. 2017:37(9).
- Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, **Song Y**, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide vs abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *Journal of Medical Economics*. 2017:20(2).
- Betts KA, Griffith J, **Song Y**, Mittal M, Joshi A, Wu EQ, Ganguli A. Network meta-analysis and cost per responder of tumor necrosis factor- $\alpha$  and interleukin inhibitors in the treatment of active ankylosing spondylitis. *Rheumatology and Therapy*. 2016:3(2).
- **Song Y**, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ. Clinical outcomes with first-line endocrine therapy or chemotherapy in postmenopausal HR+/HER2- metastatic breast cancer. *Breast Cancer: Basic and Clinical Research*. 2015:9.
- Signorovitch JE, Betts KA, **Song Y**, Sorg RA, Li J, Behl AS, Kalsekar A. Comparative efficacy and safety of daclatasvir / asunaprevir versus interferon-based regimens in genotype 1b HCV infection. *Journal of Comparative Effectiveness Research*. 2015:4(6).
- **Song Y**, Chou EL, Baecker A, You NC, Song Y, Sun Q, Liu S. Endocrine-disrupting chemicals, risk of type 2 diabetes, and diabetes-related metabolic traits: A systematic review and meta-analysis. *Journal of Diabetes*. 2015:8(4).
- Hu Y, **Song Y**, Franke AA, Hu FB, van Dam RM, Sun Q. A prospective investigation of the association between urinary excretions of dietary lignan metabolites and weight change in US women. *American Journal of Epidemiology*. 2015:182(6).
- **Song Y**, Huang YT, Song Y, Hevener AL, Ryckman KK, Qi L, LeBlanc ES, Kazlauskaitė R, Brennan KM, Liu S. Birthweight, mediating biomarkers and the development of type 2 diabetes later in life: A prospective study of multi-ethnic women. *Diabetologia*. 2015:58(6).

- **Song Y**, Hauser R, Hu FB, Franke AA, Liu S, Sun Q. Urinary concentrations of bisphenol A and phthalate metabolites and weight change: A prospective investigation in US women. *International Journal of Obesity*. 2014:38(12).
- Ryckman KK, Rillamas-Sun E, Spracklen C, Wallace RB, Garcia L, Tylavsky FA, Howard BV, Liu S, **Song Y**, LeBlanc ES, White MV, Parikh NI, Robinson JG. Ethnic differences in the relationship between birth weight and type 2 diabetes mellitus in postmenopausal women. *Diabetes & Metabolism*. 2014:40(5).
- **Song Y**, You NC, Song Y, Kang MK, Hou L, Wallace R, Eaton CB, Tinker LF, Liu S. Intake of small-to-medium-chain saturated fatty acid is associated with peripheral leukocyte telomere length in postmenopausal women. *The Journal of Nutrition*. 2013:143(6).
- **Song Y**, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. *The Journal of Nutrition*. 2013:143(2)
- He L, Tang X, **Song Y**, Li N, Li J, Zhang Z, Liu J, Yu L, Xu H, Zhang J, Hu Y. Prevalence of cardiovascular disease and risk factors in a rural district of Beijing, China: A population-based survey of 58,308 Residents. *BMC Public Health*. 2012:12.
- Cao Y, Kenfield S, **Song Y**, Rosner B, Qiu W, Sesso HD, Gaziano JM, Ma J. Cigarette smoking cessation, total and cause-specific mortality: A 22-year follow-up study in US male physicians. *Archives of Internal Medicine*. 2011:171(21).
- Wang F, Wu S, **Song Y**, Tang X, Marshall R, Liang M, Wu Y, Qin X, Chen D, Hu Y. Waist circumference, body mass index and waist to hip ratio for prediction of metabolic syndrome in Chinese. *Nutrition, Metabolism & Cardiovascular Diseases*. 2009:19(8).

## SELECTED CONFERENCE PRESENTATIONS

- Bergman M, Enejosa J, Martin N, Suboticki J, Goldschmidt D, **Song Y**, Tundia N. “Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12-week results of a Phase 3 study.” *ACR Convergence*, Virtual Congress (November 5–9, 2020)
- Hu T, Sarpong EM, **Song Y**, Done N, Orvis E, Signorovitch J, Petigara T. “Incidence of acute otitis media in children in the United States before and after the introduction of pneumococcal conjugate vaccines (PCV7 and PCV13) during 1998-2018.” *IDWeek*, Virtual Congress (October 21–25, 2020)
- Hu T, Sarpong EM, **Song Y**, Done N, Liu Q, Signorovitch J, Petigara T. “Incidence of non-invasive pneumococcal pneumonia in children in the United States before and after introduction pneumococcal conjugate vaccines (PCV7 and PCV13) during 1998-2018.” *IDWeek*, Virtual Congress (October 21–25, 2020)
- Griffin JD, **Song Y**, Yang H, Freimark J, Shah MV. “Posttransplant maintenance therapy in patients with *FLT3*-mutated (*FLT3*<sup>mut+</sup>) acute myeloid leukemia (AML): Results from a retrospective chart review study.” *European Hematology Association (EHA)*, Virtual Congress (June 11–14, 2020)

- Bensimon A, Zhong Y, Swami U, Briggs A, Young J, Feng Y, **Song Y**, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. “Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.” *Genitourinary Cancers Symposium*, San Francisco, CA (February 13–15, 2020)
- Fleischmann R, Bergman M, Tundia N, Song I-H, Suboticki J, **Song Y**, Strand V. “Patient-reported outcomes of upadacitinib versus adalimumab use in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate: 26-Week analysis of a Phase 3 study.” *ACR/ARHP Annual Meeting*, Atlanta, GA (November 8–13, 2019)
- Bergman M, Tundia N, Camp HS, Meerwein S, Schlacher C, Goldschmidt D, **Song Y**, Strand V. “Effects of upadacitinib on patient-reported outcomes after 24 weeks in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic or biologic disease-modifying anti-rheumatic drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 studies.” *ACR/ARHP Annual Meeting*, Atlanta, GA (November 8–13, 2019)
- Griffin J, Shah MV, **Song Y**, Yang H, Tang W. “Economic burden of relapse after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML): A retrospective claims-based analysis.” *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe*, Copenhagen, Denmark (November 2–6, 2019)
- Tzellos T, **Song Y**, Wang J, Yang H, Sing R, Calimlim B. “A longitudinal assessment of the impact of adalimumab on work productivity, skin pain, and quality of life measures among patients with hidradenitis suppurativa.” *European Academy of Dermatology and Venereology (EADV)*, Madrid, Spain (October 9–13, 2019)
- Bhagat H, Xu Y, Spalding J, **Song Y**, Zhao J, Zhou M, Fadli E, Yang H. “Patient preferences for triazole antifungals in the treatment of invasive mold infection: A discrete choice experiment.” *IDWeek*, Washington, DC (October 2–6, 2019)
- Strand V, Bergman M, Tundia N, Ostor A, Durez P, Song I-H, Enejosa JJ, Schlacher C, **Song Y**, Fleischman R. “Upadacitinib Improves Patient-Reported Outcomes in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results From SELECT-COMPARE.” Annual European Congress of Rheumatology (EULAR), Madrid, Spain (June 12–15, 2019)
- Schultz NM, Lowentritt B, Wilson SC, **Song Y**, Yang H, Ramaswamy K, Penson DF. “Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.” AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Diego, CA (March 25–28, 2019)
- Schultz NM, Penson DF, Wilson SC, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. “Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis.” Genitourinary Cancers Symposium (ASCO-GU), San Francisco, CA (February 14–16, 2019)
- Griffin JD, Shah MV, **Song Y**, Yang H. “Treatment patterns and healthcare resource utilization (HRU) in patients with relapsed/ refractory (R/R) *FLT3*-mutated (*FLT3*<sup>mut</sup>) and *FLT3*-wild type (*FLT3*<sup>wt</sup>) acute myeloid leukemia (AML): a multi-country medical chart study.” Annual Meeting of the American Society of Hematology (ASH), San Diego, CA (December 1–4, 2018)

- Strand V, Husni E, Singh R, Betts KA, **Song Y**, Zhao J, Griffith J, Ganguli A. “Network meta-analysis of targeted immunomodulators in the treatment of psoriatic arthritis patients without prior biologic treatment.” ACR/ARHP Annual Meeting, Chicago, IL (November 3–8, 2017)
- Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, **Song Y**, Pope J. “Patient reported outcomes of upadacitinib: Results from biologic inadequate responders (SELECT BEYOND Phase III trial).” *Annual European Congress of Rheumatology (EULAR)*, Amsterdam, Netherlands (June 13–16, 2018)
- **Song Y**, Betts KA, Singh R, Clewell J, Griffith J. “Economic evaluation of patients with psoriatic arthritis treated with adalimumab or secukinumab.” *AMCP Managed Care & Specialty Pharmacy Annual Meeting*, Boston, MA (April 23–26, 2018)
- **Song Y**, Betts KA, Singh R, Clewell J, Griffith J. “Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis.” *AMCP Managed Care & Specialty Pharmacy Annual Meeting*, Boston, MA (April 23–26, 2018)
- Kassabian V, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Schultz NM. “Healthcare resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate.” *Genitourinary Cancers Symposium (ASCO-GU)*, San Francisco, CA (February 8–10, 2018)
- Kassabian V, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Schultz NM. “Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.” *Genitourinary Cancers Symposium (ASCO-GU)*, San Francisco, CA (February 8–10, 2018)
- Griffin JD, Yang H, **Song Y**, Kinrich DB, Bui CN. “Treatment patterns and healthcare resource utilization in patients with FLT3-mut and FLT3-wt acute myeloid leukemia: a multi-country medical chart study.” *Annual Meeting of the American Society of Hematology (ASH)*, Atlanta, GA (December 9–12, 2017)
- Strand V, Husni E, Singh R, Betts BA, **Song Y**, Griffith J, Ganguli A. “Network meta-analysis of targeted immunomodulators in the treatment of biologic-naïve psoriatic arthritis.” *ACR/ARHP Annual Meeting*, San Diego, CA (November 3–8, 2017)
- Betts KA, Woolley JM, **Song Y**, Gao W, Wu EQ. “Indirect comparison of sodium zirconium cyclosilicate versus patiromer in the treatment of hyperkalemia through 48 hours.” *Kidney Week 2017 of the American Society of Nephrology (ASN)*, New Orleans, LA (October 31–November 5, 2017)
- Jemec G, **Song Y**, Yang H, Skup M, Calimlim B. “Comparison of healthcare resource utilization and costs of patients with hidradenitis suppurativa treated with adalimumab and non-biologics.” *Annual Congress of the European Academy of Dermatology and Venereology (EADV)*, Geneva, Switzerland (September 13–17, 2017)
- Fishman J, Kalilani L, **Song Y**, Swallow E, Wild I. “Dosage Titration of AED treatments and related healthcare resource use and costs: a retrospective chart review in the US.” *AMCP Managed Care & Specialty Pharmacy Annual Meeting*, Denver, CO (March 27–30, 2017)

- Kimball A, Yang M, **Song Y**, Valdecantos W, Ganguli A. “Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.” *Annual Meeting of the American Academy of Dermatology (AAD)*, Orlando, FL (March 3–7, 2017)
- Qureshi A, Yang M, **Song Y**, Zhang A, Sundaram M, Ganguli A. “High-value subpopulation for skin pain improvement in adalimumab-treated patients with moderate to severe hidradenitis suppurativa.” *Annual Meeting of the American Academy of Dermatology (AAD)*, Orlando, FL (March 3–7, 2017)
- Husni ME, Griffith J, Betts KA, **Song Y**, Ganguli A. “Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.” *ACR/ARHP Annual Meeting*, Washington, DC (November 11–16, 2016)
- Keystone EC, Betts KA, Schlacher C, **Song Y**, Ganguli A, Griffith J. “Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.” *ACR/ARHP Annual Meeting*, Washington, DC (November 11–16, 2016)
- Strand V, Tundia N, **Song Y**, Macaulay D, Fuldeore M. “Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.” *ACR/ARHP Annual Meeting*, Washington, DC (November 11–16, 2016)
- Li J, **Song Y**, Sun C, Liu S, Li Y. “Insulin resistance as a mediator for the association of protein intake with type 2 diabetes in a Chinese population.” *98th Annual Meeting and Expo of the Endocrine Society (ENDO)*, Boston, MA (April 1–4, 2016)
- Bui C, Massoudi M, Balk M, Guo J, **Song Y**, Brown B, Barlev A, Pandya BJ, Yang H. “Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer.” *AMCP Managed Care & Specialty Pharmacy Annual Meeting*, San Francisco, CA (April 19–22, 2016)
- Zhang J, **Song Y**, Zhou Z, Zhang C, Signorovitch J. “The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.” *6th European Lung Cancer Conference (ELCC)*, Geneva, Switzerland (April 13–16, 2016)
- Strand V, Husni ME, Reichmann W, Betts K, Griffith J, **Song Y**, Beppu M, Ganguli A. “Network meta-analysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis.” *Annual Meeting of the American Academy of Dermatology (AAD)*, Washington, DC (March 4–8, 2016)
- Strand V, Husni ME, Reichmann W, Betts K, Griffith J, **Song Y**, Beppu M, Ganguli A. “Network meta-analysis of tumor necrosis factor, interleukins, and phosphodiesterase-4 inhibitor in the treatment of psoriatic arthritis.” *ACR/ARHP Annual Meeting*, San Francisco, CA (November 7–11, 2015)
- **Song Y**, Hao Y, Macalalad A, Lin P, Signorovitch J, Wu E. “Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among postmenopausal women with recurrent HR+/HER2- metastatic breast cancer.” *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*, San Diego, CA (April 7, 2015)

- Signorovitch J, Betts K, **Song Y**, Sorg R, Li J, Behl A, Kalsekar A. “Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon-alpha/ribavirin-based regimens for patients infected with genotype 1b hepatitis C virus.” *24th Conference of the Asian Pacific Association for the Study of the Liver (APASL)*, Istanbul, Turkey (March 12, 2015)
- **Song Y**, You NC, Song Y, Kang M, Hou L, Wallace R, Eaton C, Tinker L, Liu S. “Relation of dietary fat intake to peripheral leukocyte telomere length in postmenopausal women.” *Society of Epidemiologic Research (SER)*, Boston, MA (June 20, 2013)
- **Song Y**, You NC, Goto A, Song Y, Hou L, Kroenke CH, Manson JE, Rohan TE, Tindle HA, Tinker LF, Liu S. “Unhealthy lifestyle in relation to peripheral leukocyte telomere length in postmenopausal women.” *2012 American Heart Association (AHA) Scientific Sessions*, Los Angeles, CA (November 6, 2012)
- **Song Y**, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. “Intake of dairy products in relation to risk and survival of prostate cancer: a 28-year follow-up study.” *2012 World Cancer Congress (WCC)*, Montréal, Canada (August 28, 2012)

#### **JOURNAL REFEREE EXPERIENCE**

Referee for *The BMJ*, the *Annals of Internal Medicine*, the *American Journal of Epidemiology*, the *Journal of Managed Care & Specialty Pharmacy*, *The American Journal of Clinical Nutrition*, *The Journal of Nutrition*, the *Journal of Diabetes*, and the *Asia Pacific Journal of Clinical Nutrition*.